FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR MutationsBusiness Wire • 09/01/20
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/28/20
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and OlderBusiness Wire • 08/21/20
Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative StrengthInvestors Business Daily • 08/18/20
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 07/30/20
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term PlayersSeeking Alpha • 07/28/20